Statement of Ownership (sc 13g)
February 14 2018 - 11:55AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
AVEO Pharmaceuticals, Inc.
|
(Name of Issuer)
|
Common stock, $0.001 par value per share
|
|
(Title of Class of Securities)
|
053588109
|
|
(CUSIP Number)
|
|
December
31, 2017
|
(Date of Event Which Requires Filing of this Statement)
|
Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:
x
Rule
13d-1(b)
o
Rule
13d-1(c)
o
Rule
13d-1(d)
*The remainder of this cover page shall be
filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
CUSIP No.
053588109
|
SCHEDULE 13G
|
Page 2
of 6 Pages
|
|
|
|
|
|
1
|
NAME OF REPORTING
PERSONS
Polar Capital LLP
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
o
(b)
o
|
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
England
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
8,077,429
|
6
|
SHARED VOTING POWER
0
|
7
|
SOLE DISPOSITIVE POWER
8,077,429
|
8
|
SHARED DISPOSITIVE POWER
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,077,429
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
o
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.8%
|
12
|
TYPE OF REPORTING PERSON
IA
|
CUSIP No. 053588109
|
SCHEDULE 13G
|
Page 3
of 6 Pages
|
Item 1.
|
|
(a) Name of Issuer
|
AVEO Pharmaceuticals, Inc.
|
|
(b) Address of Issuer’s Principal
Executive Offices
|
One Broadway, 14th Floor
Cambridge, Massachusetts 02142
Item 2.
|
|
(a) Name of Person Filing
|
Polar
Capital LLP
|
|
(b) Address
of Principal Business Office, or, if none, Residence
|
16 Palace Street
London SW1E 5JD
England
|
|
(d) Title of Class of Securities
|
Common stock, $0.001 par value per share
053588109
CUSIP No.
053588109
|
SCHEDULE 13G
|
Page 4
of 6 Pages
|
|
Item 3. If
this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
|
(a)
|
¨
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
|
|
(b)
|
¨
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
|
|
(c)
|
¨
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
|
(d)
|
¨
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
|
|
(e)
|
x
|
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
(f)
|
¨
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
(g)
|
¨
|
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
(h)
|
¨
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
(i)
|
¨
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
|
(j)
|
¨
|
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
|
|
|
(k)
|
¨
|
A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
|
|
|
|
|
CUSIP
No. 053588109
|
SCHEDULE 13G
|
Page
5 of 6 Pages
|
Item
4. Ownership
Provide the following information
regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
8,077,429
(b) Percent of class: 6.8%*
(c) Number of shares as to which
the person has:
(i) Sole power to vote
or to direct the vote: 8,077,429
(ii) Shared power to vote
or to direct the vote: 0
(iii) Sole power to dispose
or to direct the disposition of: 8,077,429
(iv) Shared power to dispose
or to direct the disposition of: 0
* Based
on 118,321,361 outstanding shares of common stock, which is the total number of shares outstanding as reported in
the Issuer’s Form 10-Q for the quarterly period ended September 30, 2017 on November 7, 2017.
Item
5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than 5 percent of the class of securities, check the following [ ].
Item
6. Ownership of More Than Five Percent on Behalf of Another Person
Not Applicable
Item
7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent
Holding Company or Control Person
Not Applicable
Item
8. Identification and Classification of Members of the Group
Not Applicable
Item
9. Notice of Dissolution of Group
Not Applicable
Item
10. Certification
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held
in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.
CUSIP No.
053588109
|
SCHEDULE 13G
|
Page 6
of 6 Pages
|
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 14, 2018
|
POLAR CAPITAL LLP
|
|
|
|
|
|
By:
|
Nicholas Farren
|
|
|
Name:
|
Nicholas Farren
|
|
|
Title:
|
Head of Operations
|
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jul 2024 to Aug 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2023 to Aug 2024